Related Experiment Video
Updated: Jun 10, 2025

Knee Arthrocentesis in Adults
Published on: February 25, 2022
Intraarticular corticosteroid injections in pediatric rheumatology: insights from specialists
Çisem Yıldız1, Batuhan Küçükali2, Sushma Shree B C3
1Department of Pediatric Rheumatology, Faculty of Medicine, Gazi University, 06560, Besevler Ankara, Turkey. cisemyildiz@hotmail.com.
Insights
Intraarticular corticosteroid injections (IACIs) are common for juvenile idiopathic arthritis (JIA), but practices vary widely among pediatric rheumatologists. Standardized protocols are needed to improve treatment efficacy and patient outcomes.
Area of Science:
- Pediatric Rheumatology
- Clinical Practice Guidelines
- Arthritis Management
Background:
- Intraarticular corticosteroid injections (IACIs) are effective for juvenile idiopathic arthritis (JIA), offering symptom relief and preventing joint deformities.
- However, significant variability exists in IACI indications, techniques, and anesthesia methods among pediatric rheumatologists, with much evidence being anecdotal.
Purpose of the Study:
- To compare intraarticular corticosteroid injection (IACI) strategies used by pediatric rheumatologists in Turkey and India.
- To identify variations in IACI practices, including agents, dosages, sites, follow-up, complications, anesthesia, and post-injection treatments.
Main Methods:
- A cross-sectional survey using a 33-item questionnaire distributed via Google Forms to pediatric rheumatologists in Turkey and India.
- Analysis of responses from 70 clinicians regarding their IACI practices for juvenile idiopathic arthritis (JIA).
Main Results:
- All surveyed clinicians use IACIs, primarily for oligoarticular JIA (100%).
- Triamcinolone hexacetonide (74.3%) was the preferred agent, often targeting the knee (15.7%). Common complications included hypopigmentation and atrophy. Ketamine was the favored anesthetic (44.2%).
- Significant practice variations were observed in ultrasound guidance use (17.1%) and post-IACI treatment strategies.
Conclusions:
- Intraarticular corticosteroid injections (IACIs) are a widely adopted treatment for oligoarticular juvenile idiopathic arthritis (JIA), but considerable practice variability persists.
- Standardized protocols, informed by further research and randomized studies, are essential to optimize IACI efficacy and improve patient outcomes in JIA management.
Abstract:
Juvenile idiopathic arthritis (JIA) refers to various types of arthritis appearing before age 16, categorized into seven subtypes by ILAR. Treatments target disease control, growth support, and quality of life, utilizing NSAIDs, DMARDs, and intraarticular corticosteroid injections (IACIs). Despite IACIs' efficacy for oligoarticular JIA, their usage and techniques vary due to anecdotal evidence. This study compares IACI strategies among pediatric rheumatologists in Turkey and India as part of a PReS Sister Center activity. A cross-sectional survey via Google Forms gathered IACI practice data from pediatric rheumatologists in Turkey and India. The 33-item questionnaire covered demographics, JIA subtypes treated with IACIs, preferred agents/dosages, injection sites, follow-up, complications, anesthesia, and post-IACI treatments. Seventy clinicians' responses were analyzed, with ethical approval from Gazi University's Ethics Committee. Seventy participants, with a mean age of 39.75 (±8.80) years responded, mostly clinical fellows (38.6%) at university hospitals (58.6%). All utilized IACIs, primarily for oligoarticular JIA (100%), with 20% exclusively using them for this subtype. Triamcinolone hexacetonide (TH) was preferred (74.3%), mainly targeting knee joints (15.7%). Initial side effect follow-up was 1-2 weeks post-IACI (65.7%), with ultrasound guidance used by 17.1%. Common complications included cutaneous hypopigmentation (38.6%) and subcutaneous atrophy (38.6%). Ketamine was the favored anesthesia (44.2%). Post-IACI, 21.4% did not add treatment for new-onset oligoarticular JIA, while NSAIDs and methotrexate were common for polyarticular JIA (51.4%).
Conclusion:
IACIs are widely utilized in pediatric rheumatology for oligoarticular JIA, yet practice variability exists. Standardized protocols through randomized studies can enhance IACI efficacy and patient outcomes.
What Is Known:
• Intraarticular corticosteroid injections (IACIs) are a widely utilized and effective treatment modality in managing oligoarticular and polyarticular juvenile idiopathic arthritis (JIA), offering rapid symptom relief and the potential to prevent long-term joint deformities. • Despite their widespread use, there is significant variability in the indications, techniques, and anesthetic methods employed for IACI administration among pediatric rheumatologists, and much of the supporting evidence remains anecdotal.
What Is New:
• This study highlights the diverse clinical practices and preferences regarding IACI use in pediatric rheumatology across two different countries, revealing considerable variations in the use of ultrasound guidance, anesthetic approaches, and corticosteroid formulations. • The findings underscore the need for standardized treatment protocols and further research to optimize IACI procedures, aiming to reduce variability and improve outcomes in the management of JIA.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Rheumatic Heart Disease III: Medical Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

